Ruthenium metallodendrimer against triple-negative breast cancer in mice

IF 4.2 2区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Nanomedicine : nanotechnology, biology, and medicine Pub Date : 2023-09-01 DOI:10.1016/j.nano.2023.102703

Sylwia Michlewska PhD , Dagmara Wójkowska PhD , Cezary Watala Professor , Elżbieta Skiba PhD , Paula Ortega Professor , Francisco Javier de la Mata Professor , Maria Bryszewska Professor , Maksim Ionov Professor

引用次数: 0

Abstract

Carbosilane metallodendrimers, based on the arene Ru(II) complex (CRD13) and integrated to imino-pyridine surface groups have been investigated as an anticancer agent in a mouse model with triple-negative breast cancer. The dendrimer entered into the cells efficiently, and exhibited selective toxicity for 4T1 cells. In vivo investigations proved that a local injection of CRD13 caused a reduction of tumour mass and was non-toxic. ICP analyses indicated that Ru(II) accumulated in all tested tissues with a greater content detected in the tumour.

Abstract Image

查看原文本刊更多论文

钌金属树枝状大分子抗小鼠癌症三阴性。

基于芳烃Ru（II）复合物（CRD13）并整合到亚氨基吡啶表面基团的碳硅烷金属树枝状聚合物已被研究为癌症三阴性小鼠模型中的抗癌剂。树枝状大分子有效地进入细胞，并表现出对4T1细胞的选择性毒性。体内研究证明，局部注射CRD13可减少肿瘤质量，且无毒。ICP分析表明，Ru（II）在所有测试组织中积累，在肿瘤中检测到更高的含量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanomedicine : nanotechnology, biology, and medicine 工程技术-纳米科技

CiteScore

11.10

自引率

0.00%

发文量

133

审稿时长

42 days

期刊介绍： The mission of Nanomedicine: Nanotechnology, Biology, and Medicine (Nanomedicine: NBM) is to promote the emerging interdisciplinary field of nanomedicine. Nanomedicine: NBM is an international, peer-reviewed journal presenting novel, significant, and interdisciplinary theoretical and experimental results related to nanoscience and nanotechnology in the life and health sciences. Content includes basic, translational, and clinical research addressing diagnosis, treatment, monitoring, prediction, and prevention of diseases.